Get access

Milestones in atypical and secondary Parkinsonisms

Authors

  • Gregor K. Wenning MD, PhD, MSc,

    Corresponding author
    1. Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck, Austria
    • Division of Clinical Neurobiology, Department of Neurology, Medical University, Anichstraße 35, 6020 Innsbruck, Austria
    Search for more papers by this author
  • Irene Litvan MD,

    1. Department of Neurology, University of Louisville, Louisville, Kentucky, USA
    Search for more papers by this author
  • Eduardo Tolosa MD

    1. Neurology. Service, Institut Clínic de Neurociències, Hospital Clínic Universitari, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain
    Search for more papers by this author

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

Abstract

During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. Although treatment options are largely limited to date, remarkable progress has occurred through advances in the fields of molecular biology and diagnostic neuroimaging, resulting in intense preclinical drug discovery programs. Early-investigation-assisted clinical diagnosis has become more crucial than ever because disease-modifying therapies will hopefully become available within this decade. © 2011 Movement Disorder Society

Ancillary